Infectious disease is often untreatable, even when caused by a pathogen that is not resistant to antibiotics. This is the paradox, and the problem that we aim to solve. Microbial populations produce persisters, dormant cells that are not mutants, but phenotypic variants of the wild type that are tolerant to antibiotics. It seemed possible that the presence of persisters could explain the treatment paradox: an antibiotic eliminates most of the population, and once its concentration drops, the surviving persisters start dividing and reestablish the infection. However, prolonged treatment of persisters in vitro with antibiotics which should emulate the in vivo therapy eliminates these dormant cells. The hypothesis. We hypothesize that the agent responsible for untreatable infections is a super-persister cell which carries a high-persister mutation and has induced stress responses. Repeated application of high levels of antibiotics in vitro selects for E. coli hip (high-persister) mutants that have an increased level of persister cells. According to our data, the hip cells are also more drug-tolerant as compared to wild type persisters. We reasoned that periodic application of lethal doses of antibiotics to patients with chronic infections will similarly select for hip mutants. Analysis of longitudinal isolates from a cystic fibrosis patient infected with P. aeruginosa showed that late, but not early isolates are indeed hip mutants. It seems possible that therapy with repeated doses of antibiotic selects hip mutants in many if not all pathogens, and it is these presently overlooked tolerant (rather than resistant) mutants that are ultimately responsible for morbidity of the disease and for the death of a patient. Apart from hip mutations, there seems to be another overlooked, but potentially critical component contributing to tolerance - stress responses. So far, we have known of two seemingly opposite strategies of cell survival - dormancy, which shuts down functions and creates persister cells;and induction of stress responses (heat shock, DNA repair, oxidation stress, etc.) that actively protect the cell from noxious conditions. We propose that these two strategies actually complement each other. If a persister is formed in a population that had expressed stress proteins, then it will shut down antibiotic targets, while retaining protective proteins which will help it survive. In the body, a pathogen is exposes to oxidants, DNA damaging agents, membrane acting agents, and it seems that expression of several stress responses is a norm. The ultimate survivor is then a persister carrying a hip mutation which is formed in a population expressing stress responses. It is this super-persister that is probably responsible for much of untreatable disease and will be the focus of our investigation. The experimental plan will address the following interrelated questions: are hip mutants an important part of chronic infection? Are there super-persisters that combine hip mutations with expression of stress responses? Is tolerance, similarly to resistance, a transmissible trait?
In this project, we will search for mutants of pathogens that are able to enter into a state of dormancy highly tolerant to existing antibiotics. Our findings are likely to change the way we view infectious diseases and will provide rational approaches for discovering drugs that completely eradicate the infection.
|Schumacher, Maria A; Balani, Pooja; Min, Jungki et al. (2015) HipBA-promoter structures reveal the basis of heritable multidrug tolerance. Nature 524:59-64|
|Ling, Losee L; Schneider, Tanja; Peoples, Aaron J et al. (2015) A new antibiotic kills pathogens without detectable resistance. Nature 517:455-9|
|Shan, Yue; Lazinski, David; Rowe, Sarah et al. (2015) Genetic basis of persister tolerance to aminoglycosides in Escherichia coli. MBio 6:|
|Sharma, Bijaya; Brown, Autumn V; Matluck, Nicole E et al. (2015) Borrelia burgdorferi, the Causative Agent of Lyme Disease, Forms Drug-Tolerant Persister Cells. Antimicrob Agents Chemother 59:4616-24|
|Gavrish, Ekaterina; Sit, Clarissa S; Cao, Shugeng et al. (2014) Lassomycin, a ribosomally synthesized cyclic peptide, kills mycobacterium tuberculosis by targeting the ATP-dependent protease ClpC1P1P2. Chem Biol 21:509-18|
|Fleck, Laura E; North, E Jeffrey; Lee, Richard E et al. (2014) A screen for and validation of prodrug antimicrobials. Antimicrob Agents Chemother 58:1410-9|
|Mulcahy, Lawrence R; Isabella, Vincent M; Lewis, Kim (2014) Pseudomonas aeruginosa biofilms in disease. Microb Ecol 68:1-12|
|Keren, Iris; Wu, Yanxia; Inocencio, Julio et al. (2013) Killing by bactericidal antibiotics does not depend on reactive oxygen species. Science 339:1213-6|
|Conlon, B P; Nakayasu, E S; Fleck, L E et al. (2013) Activated ClpP kills persisters and eradicates a chronic biofilm infection. Nature 503:365-70|
|Lafleur, Michael D; Sun, Lingmei; Lister, Ida et al. (2013) Potentiation of azole antifungals by 2-adamantanamine. Antimicrob Agents Chemother 57:3585-92|
Showing the most recent 10 out of 16 publications